Interim Management Statement on the First Three Months of 2024
First efficacy data from the clinical trial with HDP-101…
Calliditas Announces Positive NefIgArd Open Label Extension Results
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm:…
Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors
V-Bio Ventures leads international syndicate which includes…
Vivet Therapeutics to Participate and Present at Upcoming Scientific and Investor Conferences in April through to June 2024
Paris, France, April 23, 2024 – Vivet Therapeutics (“Vivet”),…
AMSilk strengthens management team with key hires of Ralph Fraundorfer and Ctibor Kohutovic to Management Board
Neuried, Germany, 23 April 2024: AMSilk GmbH (“AMSilk”),…
SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT
Financing co-led by Forbion, HealthCap and new investor Bioqube…
Outrun Therapeutics launches with a $10m seed financing from M Ventures and MP Healthcare Venture Management to develop a protein stabilisation pipeline
Proprietary E3 ligase platform to enable protein stabilisation…
4SC publishes Q1 2024 report
Planegg-Martinsried, Germany, 18 April 2024 – 4SC AG (4SC,…
Xeltis Announces Latest Results from aXess Trials to be Presented at 46th Annual Charing Cross Symposium
Two key presentations by leading KOLs highlight positive…
4SC AG: Paediatric Investigation Plan waiver for resminostat from the UK MHRA received
Removes the requirement to conduct paediatric clinical studies…
4SC: Landmark RESMAIN study data presented at the 5th World Congress of Cutaneous Lymphomas
Resminostat (Kinselby) as a maintenance therapy is now clinically…
SpliceBio to Attend and Present at Key Scientific and Investor Conferences in April to June 2024
BARCELONA, 10 April 2024 – SpliceBio, a genetic medicines company…
Vivet Therapeutics Doses First Patient in Cohort 2 in Phase 1/2 GATEWAY Clinical Trial for Treatment of Wilson Disease
Vivet Therapeutics Doses First Patient in Cohort 2 in Phase 1/2…
Medicxi Announces $40m investment in D3 Bio
Investment will support development of a differentiated…
Heidelberg Pharma to host R&D Webinar following novel data presented at AACR
Ladenburg, Germany, 5 April 2024 – Heidelberg Pharma AG (FSE:…
We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York